Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan
GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus…
Read More...
Read More...
